A Quality of Life Study re Management of Malignant Pleural Effusions

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

149 participants

Study Classification

OBSERVATIONAL

Study Start Date

2004-08-31

Study Completion Date

2013-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There is much data in the literature regarding optimal treatment approaches for malignant pleural effusions as assessed by patient outcomes. However, data on quality of life and satisfaction with treatment from the patient's perspective is not available.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pleural Catheters Versus Thoracoscopic Pleurodesis

NCT01117740

Lung Cancer

COMPLETED

Quantitative Diaphragmatic Ultrasound Evaluation in Pleural Effusions : A Feasability Study

NCT04264325

Malignant Pleural Effusion Lung Neoplasms

COMPLETED

Management of Malignant Pleural Effusion - Indwelling Pleural Catheter or Talc Pleurodesis

NCT02825095

Pleural Effusion, Malignant Lung Neoplasms

UNKNOWN EARLY_PHASE1

Out Patient Talc Slurry Via Indwelling Pleural Catheter for Malignant Pleural Effusion Vs Usual Inpatient Management

NCT02517749

Pleural Effusion, Malignant

COMPLETED NA

Management of Malignant Pleural Effusion With Indwelling Pleural Catheter Versus Silver Nitrate Pleurodesis

NCT03781908

Pleural Effusion, Malignant

UNKNOWN PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will compare various treatment strategies in the management of malignant pleural effusions with respect to:

1. Primary endpoint: the successful palliation of symptomatic pleural effusions as assessed by the London Chest Activity of Daily Living Scale (LCADLS)
2. Secondary endpoints:

i) impact of treatment on patient quality of life as assessed by the Functional Assessment of Chronic Illness Therapy - Palliative patient (FACIT-PAL) questionnaire ii) Assessment of patient satisfaction with treatment received via Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction (FACIT-TS) questionnaire iii)Pleurodesis success rates assessed by 2 and 6-week effusion control rates on CXR iv) Requirement of further hospitalizations or procedures for the treatment of recurrent effusions v) Comparison of morbidity and mortality rates for differing treatment approaches vi) comparison of cost in a Canadian health care setting for differing treatment approaches

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malignant Pleural Effusions

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LCADLS, FACIT-PAL, FACIT-TS questionnaires

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* symptomatic pleural effusion
* history of malignant disease
* age greater that 18 years
* consent to participate in study

Exclusion Criteria

* significant ipsilateral endobronchial disease
* prior ipsilateral, intra-pleural therapy, as defined by: prior chest tube placement for effusion, prior attempt at chemical/surgical pleurodesis, prior surgical pleurectomy
* active pulmonary or pleural infection
* granulocytes \< 1500/mm3, platelets \< 50,000/mm3
* systemic chemotherapy within 2 weeks
* allergy to talc

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No